Cargando…

PET Imaging in Huntington’s Disease

To date, little is known about how neurodegeneration and neuroinflammation propagate in Huntington’s disease (HD). Unfortunately, no treatment is available to cure or reverse the progressive decline of function caused by the disease, thus considering HD a fatal disease. Mutation gene carriers typica...

Descripción completa

Detalles Bibliográficos
Autores principales: Roussakis, Andreas-Antonios, Piccini, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927896/
https://www.ncbi.nlm.nih.gov/pubmed/26683130
http://dx.doi.org/10.3233/JHD-150171
_version_ 1782440332579831808
author Roussakis, Andreas-Antonios
Piccini, Paola
author_facet Roussakis, Andreas-Antonios
Piccini, Paola
author_sort Roussakis, Andreas-Antonios
collection PubMed
description To date, little is known about how neurodegeneration and neuroinflammation propagate in Huntington’s disease (HD). Unfortunately, no treatment is available to cure or reverse the progressive decline of function caused by the disease, thus considering HD a fatal disease. Mutation gene carriers typically remain asymptomatic for many years although alterations in the basal ganglia and cortex occur early on in mutant HD gene–carriers. Positron Emission Tomography (PET) is a functional imaging technique of nuclear medicine which enables in vivo visualization of numerous biological molecules expressed in several human tissues. Brain PET is most powerful to study in vivo neuronal and glial cells function as well as cerebral blood flow in a plethora of neurodegenerative disorders including Parkinson’s disease, Alzheimer’s and HD. In absence of HD–specific biomarkers for monitoring disease progression, previous PET studies in HD were merely focused on the study of dopaminergic terminals, cerebral blood flow and glucose metabolism in manifest and premanifest HD–gene carriers. More recently, research interest has been exploring novel PET targets in HD including the state of phosphodiesterse expression and the role of activated microglia. Hence, a better understanding of the HD pathogenesis mechanisms may lead to the development of targeted therapies. PET imaging follow–up studies with novel selective PET radiotracers such as (11)C-IMA–107 and (11)C-PBR28 may provide insight on disease progression and identify prognostic biomarkers, elucidate the underlying HD pathology and assess novel pharmaceutical agents and over time.
format Online
Article
Text
id pubmed-4927896
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-49278962016-06-30 PET Imaging in Huntington’s Disease Roussakis, Andreas-Antonios Piccini, Paola J Huntingtons Dis Review To date, little is known about how neurodegeneration and neuroinflammation propagate in Huntington’s disease (HD). Unfortunately, no treatment is available to cure or reverse the progressive decline of function caused by the disease, thus considering HD a fatal disease. Mutation gene carriers typically remain asymptomatic for many years although alterations in the basal ganglia and cortex occur early on in mutant HD gene–carriers. Positron Emission Tomography (PET) is a functional imaging technique of nuclear medicine which enables in vivo visualization of numerous biological molecules expressed in several human tissues. Brain PET is most powerful to study in vivo neuronal and glial cells function as well as cerebral blood flow in a plethora of neurodegenerative disorders including Parkinson’s disease, Alzheimer’s and HD. In absence of HD–specific biomarkers for monitoring disease progression, previous PET studies in HD were merely focused on the study of dopaminergic terminals, cerebral blood flow and glucose metabolism in manifest and premanifest HD–gene carriers. More recently, research interest has been exploring novel PET targets in HD including the state of phosphodiesterse expression and the role of activated microglia. Hence, a better understanding of the HD pathogenesis mechanisms may lead to the development of targeted therapies. PET imaging follow–up studies with novel selective PET radiotracers such as (11)C-IMA–107 and (11)C-PBR28 may provide insight on disease progression and identify prognostic biomarkers, elucidate the underlying HD pathology and assess novel pharmaceutical agents and over time. IOS Press 2015-12-11 /pmc/articles/PMC4927896/ /pubmed/26683130 http://dx.doi.org/10.3233/JHD-150171 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Roussakis, Andreas-Antonios
Piccini, Paola
PET Imaging in Huntington’s Disease
title PET Imaging in Huntington’s Disease
title_full PET Imaging in Huntington’s Disease
title_fullStr PET Imaging in Huntington’s Disease
title_full_unstemmed PET Imaging in Huntington’s Disease
title_short PET Imaging in Huntington’s Disease
title_sort pet imaging in huntington’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927896/
https://www.ncbi.nlm.nih.gov/pubmed/26683130
http://dx.doi.org/10.3233/JHD-150171
work_keys_str_mv AT roussakisandreasantonios petimaginginhuntingtonsdisease
AT piccinipaola petimaginginhuntingtonsdisease